Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: Rheumatoid Arthritis
In brief
This is a double-blind, randomized, placebo- and active-controlled study investigating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous (SC) doses of LFD-200. The study design includes: a single ascending dose (SAD) study in up to 66 adult healthy participants (HPs) to investigate the effects of a single SC dose, with a 30-day follow-up; a multiple ascending dose (MAD) study in up to 40 HPs to assess up to 4 weekly SC doses, with a 30-day follow-up after the last dose; and a MAD study in up to 70 participants with moderate to severe rheumatoid arthritis (RA) to evaluate up to 13 weekly SC doses, with a 30-day follow-up after the last dose.
Key facts
- Study ID
- NCT07207954
- Run by
- Lifordi Immunotherapeutics, Inc.
- People needed
- 176
- Starts
- 2025-10-06
- Expected to finish
- 2027-07-16
- Last updated by the study team
- 2026-07-28
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.
Where it is running
- Clinical Republican Hospital "Timofei Mosneaga", ARENSIA E.M. — Chisinau, Moldova (enrolling)
- "ARENSIA EXPLORATORY MEDICINE" LIMITED LIABILITY COMPANY, Medical Center, Department of Clinical Trials — Kyiv, Ukraine (enrolling)
- Medical Clinical Investigational Center "Medical Center Health Clinic", LLC — Vinnytsia, Ukraine (enrolling)
- Arensia Exploratory Medicine LLC — Tbilisi, Georgia (enrolling)
- MICS Centrum Medyczne Torun - MICS - PPDS — Torun, Poland
- Nucleus Network — Melbourne, Australia
- Centrum Medyczne Reuma Park — Warsaw, Poland
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.